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Interaction of IGF-I and 1a,25(OH)2D3 on receptor expression and
growth stimulation in rat growth plate chondrocytes. Growth plate
cartilage cells express receptors for, and are affected by both IGF-I and
1a,25(OH)2D3. The studies were undertaken to investigate interaction
between these two hormone systems, that is, (i) to study effects of
1a,25(OH)2D3 on IGF-type 1 receptors (IGFIR), on IGF-I stimulated cell
replication, colony formation, and on alkaline phosphatase activity (AP),
and conversely, (ii) to study the effect of IGF-I on vitamin D receptor
(VDR) expression on 1a,25(OH)2D3 stimulated growth parameters and
on AP activity. Freshly isolated rat tibial chondrocytes were grown in
monolayer cultures, (serum-free) or in agarose stabilized suspension
cultures (0.1% FCS). Vitamin D receptor and IGFIR were visualized by
immunostaining with the monoclonal antibody (mAb) 9A7g and mAb
aIR3, respectively, and quantitated by RT-PCR for mRNA and by
Scatchard analysis using [3H]-1,25(OH)2D3 and [
125I]-aIR3. Cell prolifer-
ation was measured by [3H]-thymidine incorporation, growth curves in
monolayer cultures, and by colony formation in agarose-stabilized suspen-
sion cultures. IGF-I dose-dependently increased [3H]-thymidine incorpo-
ration. 1a,25(OH)2D3, but not 1b,25(OH)2D3 was stimulatory at low
(10212 M) and slightly inhibitory at high (1028 M) concentrations. The
effect of IGF-I was additive to that of 1a,25(OH)2D3 [IGF-I 60 ng/ml,
181 6 12.7; 1a,25(OH)2D3 10
212 M, 181 6 9.8%, IGF-I 1 1a,25(OH)2D3,
247 6 16.7%; P , 0.05 by ANOVA] and specifically obliterated by
polyclonal IGF-I antibody (AB-1). Interaction could also be confirmed in
suspension cultures. IGFIR mRNA and [125I]-aIR3 binding was increased
by low (10212 M) but not by high (1028 M) concentrations of
1a,25(OH)2D3. Homologous up-upregulation by IGF-I (60 ng/ml) was
specifically inhibited by AB-1 and markedly amplified by coincubation
with 1a,25(OH)2D3 (10
212 M). Immunostaining with aIR3 showed specific
IGFIR expression in rat growth cartilage, but not liver tissue. Stimulation
of chondrocytes with 1a,25(OH)2D3 or IGF-I suggested some increase of
receptor expression in single cells, but the predominant effect was
increased recruitment of receptor positive cells. Vitamin D receptor
expression was markedly stimulated (fourfold) by IGF-I (60 ng/ml), but
not IGF-II and inhibited by actinomycin D. This study shows that IGF-I
and 1a,25(OH)2D3 mutually up-regulate their respective receptors in
growth plate chondrocytes. In parallel, they have additive effects on cell
proliferation and colony formation suggesting independent effector path-
ways.
Maintenance of longitudinal bone growth and normal function
of the growth plate cartilage cells is dependent on several
paracrine and autocrine hormonal stimuli including the vitamin D
system and the somatotropic hormone axis. It is well established
that growth plate cells are targets for growth hormone [1, 2] and
insulin-like growth factors (IGFs) [3, 4]. Growth hormone (GH)-
deficiency results in (i) low concentrations of circulating IGF-I,
and (ii) low local (paracrine) secretion of IGF-1 by chondrocytes
[3, 5]. According to the dual-effector theory proposed by Green,
Morikawa and Nixon [6], endocrine secreted GH induces differ-
entiation of prechondrocytes, whereas IGF-I (the product of
paracrine secretion) stimulates clonal expansion of growth plate
chondrocytes [7].
Altered metabolism of vitamin D, such as in vitamin D defi-
ciency rickets, vitamin D-dependent rickets type I and chronic
renal failure, is characterized by disturbances of the growth plate,
such as disturbed mineralization and abnormal architecture,
resulting in a stunted growth. Restoration of active vitamin D
levels results in catch-up growth in rickets. In vitro studies clearly
demonstrate that growth plate chondrocytes express the vitamin
D receptor (VDR) [8, 9], and that 1a,25(OH)2D3 modulates
growth cartilage cell proliferation, that is, stimulation at physio-
logical concentrations (10212 M) and inhibition at high concentra-
tions (1028 M) [10].
Chronic renal failure is characterized by disturbed vitamin D
metabolism [11], but also by an insensitivity to the action of
somatotropic hormones [12]. Despite normal levels of circulating
IGF-I measured by RIA, the biological activity of IGF-I is
reduced [12]. Treatment with supraphysiological doses of GH
increases IGF-I levels and restores IGF-I bioactivity [13]. In
parallel, GH stimulates renal 1a-hydroxylase via IGF-dependent
pathways [14], demonstrating interaction between the somato-
tropic and calcitropic hormone systems. Thus, simultaneous dis-
turbance in the action of IGF-I and vitamin D can be implicated
in various pathologic growth conditions. This study investigates
possible interactions of these two hormone systems at the level of
the growth cartilage cells, using an in vitro model.
METHODS
Materials
1a,25(OH)2-[26,27-methyl-
3H]cholecalciferol (158 Ci/mmol)
was obtained from Amersham Buchler (Braunschweig, Germa-
ny); unlabeled 1a,25(OH)2D3 and 1b,25(OH)2D3, were gifts from
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Dr. Calcanis and Dr. Uskokovic (Hoffmann-La Roche, Germany
and USA); [3H]-thymidine (40 Ci/mmol); hydroxyapatite, dithio-
threitol, and Triton X-100, were from Sigma Chemical Co.
(Munich, Germany); F-12 and DMEM medium, PBS, gentamicin,
clostridium collagenase (EC 3.4.24.3), DNAse I (EC 3.1.21.1),
trypan blue were from Boehringer (Mannheim, Germany). DNase
I (FPLC pure) for DNA digestion before reverse transcription
was from Pharmacia Biotech (Freiburg, Germany). Human re-
combinant IGF-I and IGF-II were gifts from Pharmacia GmbH,
Erlangen, Germany; the monoclonal antibody aIR3 was pur-
chased from Dianova (GR 11 L) as was VDR-mab 9A7g2b.
Polyclonal antibody for IGF-I (AB-1) was supplied by W. Blum
(Gieben, Germany). Standard low (SL) and low gel temperature
(LGT) agarose was purchased from BioRad (Richmond, VA,
USA). Fetal calf serum (FCS) was from Seromed (Berlin, Ger-
many); 1,25(OH)2D3 in FCS was 1.1 3 10
210 M [10]. Alpha IR3
was labeled with [125I] using standard techniques (Fa. Immundi-
agnostik, Bensheim, Germany). Primers and Superscript II re-
verse transcriptase were purchased from Gibco BRL (Eggenheim,
Germany), Taq Polymerase from Pharmacia (Erlangen, Germa-
ny), and GATC Biocycle Sequencing Kit from GATC (Konstanz,
Germany).
Cell cultures
Isolation of chondrocytes. Epiphyseal chondrocytes from 80 g
Sprague-Dawley rats were isolated and cultured as described [10,
15] using a modified technique of Benya and Shaffer [16] and
Lindahl et al [17]. Viability determined by the trypan blue
exclusion technique, always exceeded 90%. Dissociated cells were
counted using a Neubauer chamber.
Monolayer cultures. Cells were cultured in 35 mm plastic dishes
(Falcon Labware Oxnard, CA, USA) for proliferation assays, on
glass cover slips for immunocytology, in 100 mm dishes for VDR
determination, in 24 multiwell plates for AP measurements and
for IGF type-1 receptor determinations as described [10, 15]. In
previous studies we demonstrated that the majority of cells under
these culture conditions correspond to proliferative chondrocytes
in the growth plate as assessed by morphological and biochemical
characteristics [10, 18]. With prolonged culture, chondrocytes
continue to differentiate into hypertrophic cells and mineralize
the matrix as shown previously [18].
Agarose stabilized suspension cultures. Cells were cultured in 60
mm Petri dishes (Falcon Plastics) in agarose according to Benya
and Schaffer [16] as described [10, 15]. The cells were diluted with
F-12/DMEM medium, containing 0.1% FCS and 0.2% BSA and
were then mixed with low gel temperature (LGT) agarose to give
a final cell concentration of 80,000 cells/ml in 0.5% LGT agarose.
Three milliliter of F-12/DMEM medium supplemented with 0.1%
FCS or 10% FCS and various concentrations of IGFs or vitamin
D metabolites (or solvent control) as indicated were added on top.
The medium was changed every other day. The cultures were
screened for adherent cell clusters of more than three cells. No
such clusters were seen at the start of culture in any experiment
presented in this study.
Assays of chondrocyte growth and proliferation
Clonal assay. Suspension cultures were terminated by fixation in
buffered formaldehyde (4%). Colonies were counted in 100
squares (2 mm grid) for each dish. A cell colony was defined as a
cluster of cells with matrix stained by alcian blue as described [10,
15, 17].
[3H]-thymidine assay. Incorporation of [3H]-thymidine into
DNA was determined as radioactivity in TCA-precipitable mate-
rial as described previously [10]. Prior to the start of experiments
cells were synchronized by maintaining them under serum free
conditions for 24 hours. Medium was changed (0.2% BSA) and
hormones or solvent added as indicated for 6 to 48 hours. Two
mCi of [3H]-thymidine were added for the last four hours. Cells
were counted in parallel cultures.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
RNA preparation. Total RNA from cultured cells was isolated
by the RNA-Cleant method (Angewandte Gentechnologie
Systeme, Heidelberg, Germany) following the instructions of the
manufacturers, and quantitated by measuring the absorbency at
260 nm.
Reverse transcriptase (RT)-polymerase chain reaction (PCR) am-
plification of vitamin D receptor (VDR) and insulin-like growth
factor type-1 receptor (IGFIR). RT-PCR was performed as de-
scribed [19]. RT and PCR primers were deduced from rat VDR
[20] and IGFIR sequence [21]. After DNase digestion, 2 mg of
total RNA were reverse transcribed into cDNA using specific
primers for VDR (R1: 59-CCGAACACCTCCAGCACAAG-39)
and IGFIR (R1: 59-CTCGGCGTTGGGGATGTTG-39). After
cDNA synthesis, excess primers were removed and PCR amplifi-
cation was performed using the cDNA template with the specific
primers pairs (VDR: F1: 59-GCCCACCACAAGACCTAT-39 and
R2: 59-CCTTTTGGATGCTGTAACTG-39; IGFIR: F1: 59-TC-
CACATCCTGCTCATCTCC-39 and R2: 59-TGCCTTCCCACA-
CACACTTG-39). The amplification profile consisted of denatur-
ation at 94°C for 30 seconds, annealing at 58°C for 30 seconds, and
extension at 72°C for 30 seconds for all primers after a five-minute
denaturation step at 94°C in a Perkin Elmer Gene Amp PCR
System 9600. The amplified products (32 cycles, 297 bp for VDR
and 30 cycles, 490 bp for IGFIR) were detected by electrophoresis
in a 2% agarose gel and visualized by ethidium bromide staining
and ultraviolet transillumination. As a control, b-actin mRNA was
also reverse transcribed and the resulting cDNA amplified using
specific primers [19] and following the same protocol resulting in
a PCR product of 405 bp. Control reactions performed by
omitting reverse transcriptase or template RNA showed no
reaction product. The cycle products were within the linear
logarithmic phase of the amplification curves. The optical densi-
ties of the PCR products were analyzed by a commercial available
computed program (Bio-1D V.96.; Vilber Lourmat, France).
Results were normalized for the density of b-actin. The PCR
products were verified by sequencing.
Assay of 1 a,25(OH)2D3 receptor and IGF type-1 receptor
expression
KTED extracts. Cell extracts were prepared as described else-
where [10, 15]. In brief, cell suspensions (1 3 107 cells/ml) were
homogenized in 0.4 M KTED buffer (0.4 M KCl, 10 mM Tris HCl,
1.5 mM EDTA, 2 mM dithiothreitol, 10 mM sodium molybdate, pH
7.4). A purified fraction was prepared by centrifugation at 205,000
g for 30 minutes. The supernatant was used for binding studies.
Saturation analysis according to Scatchard [22] was carried out as
described [10, 23].
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Assay of IGF type-1 receptor expression. Specific binding of
[125I]-labeled monoclonal antibody aIR3 was utilized to quanti-
tate the level of IGFIR expression. Saturation analysis with
[125I]-aIR3 was carried out as described [24]. Chondrocytes were
grown to subconfluence in 24-well tissue plates. After two washes
in F-12/DMEM 1/1 (vol/vol) (0.2% BSA, 1.2 mmol/liter nominal
calcium concentration), increasing concentrations (0.1 to 1.5 nM)
of [125I]-aIR3 alone or with 100-fold molar excess of unlabeled
aIR3 were incubated with the cells for 60 minutes at 4°C. After
three washes with ice-cold F-12/DMEM, the cell associated
monoclonal antibody (mAb) [125I]-aIR3 was eluted with 1 N
NaOH. Glacial acetic acid was used for neutralization. [125I] was
determined in both the cell lysate and the supernatant. The
radioactivity was measured in a liquid scintillation counter. Cell
counts were performed in parallel cultures.
Immunocytochemistry
Immunocytochemical demonstration of vitamin D receptor. The
VDR-specific rat mab 9A7g, which was raised against chicken
intestinal VDR [25], was used for immunocytochemistry as de-
scribed [10, 18]. Immunostaining was applied using the labeled
avidin-biotin technique as described [26]. In brief, chondrocytes
grown on glass cover slips were fixed in 3.7% paraformaldehyde
(4°C, 10 min) followed by methanol (4°C, 4 min) and acetone 1%
H2O2 (4°C, 4 min) and incubated with the primary antibody,
diluted 1:1 in PBS, 0.05% BSA, 0.05% Triton X-100, pH 7.
Visualization was obtained with DAB.
Immunocytochemical demonstration of insulin-like growth factor
type-1 receptor (IGFIR). Immunohistochemical and cytochemical
demonstration of the IGFIR was performed with a modification
of the method of Raile et al [27] and Bentham et al [28]. Cryostat
sections of freshly isolated tibial growth plates from rabbits (500
g) or rats (80 g) and rat liver (two-month-old animals) or
chondrocytes grown on glass cover slips were fixed in 3.7%
paraformaldehyde (4°C, 10 min) followed by methanol (4°C, 4
min) and acetone 1% H2O2 (1°C, 1 min), and incubated with the
monoclonal antibody aIR3 at final dilution of 1:100. Further
processing was as described [27].
Statistics
Data are given as mean 6 SD. Statistical analysis was carried out
using ANOVA or the Mann-Whitney-U-test as appropriate by
Sigma-Stat statistical software (Fa. Jandel, Germany).
RESULTS
Regulation of IGF-I type-1 receptor expression in chondrocytes
by 1a,25(OH)2D3
IGFIR expression was independently assessed by detection of
IGFIR mRNA by RT-PCR, immune staining, and binding studies
using unlabeled and [125I]-labeled aIR3 (Table 1). Primary cul-
tures of growth plate chondrocytes expressed IGFIR mRNA (Fig.
1A). Amplification of the specific mRNA using primers generated
a 490 bp fragment. The monoclonal antibody aIR3 reacted with
rat and rabbit growth plate chondrocytes in a specific manner,
whereas rat liver was not stained (not shown). Figure 2 shows
immune staining of chondrocyte monolayer cultures with aIR3
under basal conditions and after incubation with IGF-I (60 ng/ml)
or 1a,25(OH)2D3 (10
212 M) for 24 hours. Staining was markedly
stimulated by 1a,25(OH)2D3, by IGF-I, and most expressed by
IGF-I plus 1a,25(OH)2D3. The staining was not only more intense
in single cells, but also a higher proportion of cells were positive
for aIR3 [control 13.2 6 1.2%, 1a,25(OH)2D3 29.8 6 2.9%, IGF-I
29.3 6 0.7% and 1a,25(OH)2D3 1 IGF-I to 37.3 6 2.5%, P , 0.05
versus control and 1a,25(OH)2D3 alone or IGF-I alone versus
1a,25(OH)2D3 1 IGF-I].
Maximum specific binding of [125I]-aIR3 increased nearly
threefold upon preincubation for 48 hours with IGF-I (60 ng/ml)
and by preincubation with 10212 M, but not with 1028 M
1a,25(OH)2D3. Coincubation with both hormones (10
212 M
1a,25(OH)2D3 and 60 ng/ml IGF-I) further enhanced [
125I]-aIR3
binding. There was no change in apparent receptor affinity (Fig.
3). In contrast, IGFIR mRNA was slightly stimulated only by
1a,25(OH)2D3 at 10
212 M after 24 hours incubation (Fig. 1A).
The homologous increase of [125I]-aIR3 binding was prevented by
specifically binding IGF-I with AB-1, while the controls (AB-1
alone and third party antimouse IgG) were not affected. Addition
of IGF-I (60 ng/ml) to the culture 30 minutes prior to the assay
significantly reduced [125I]-aIR3 binding (Table 1). After 48 hours
incubation with IGF-I (60 ng/ml) specific [125I]-aIR3 binding was
increased (Table 1). IGF-I in the supernatant at basal conditions
(0.2% BSA) was 0.16 6 0.07 ng/ml. During the 48-hour incubation
period preceded by 24 hours synchronization of the cell cycle in
serum-free medium, no significant increase in cell number (data
not given) and no increase in protein content (initial 1.60 mg/106
cells; final 1.99 mg/106 cells, P . 0.05) were found. Vitality of cells,
as assessed by Trypan blue exclusion, in this and the following
experiments always exceeded 96%.
Effect of 1a,25(OH)2D3 and IGF-I on chondrocyte DNA
replication in monolayer cultures
Incubation for 48 hours with increasing concentrations of IGF-I
caused a biphasic effect on [3H]-thymidine incorporation with a
maximum at 60 ng/ml (Table 2 and Fig. 4). The increase was time
dependent with a maximum at 24 hours (0 hr 13,477 6 752
cpm/well, 12 hr 33,929 6 1251, 24 hr 38,130 6 989, P , 0.01,
ANOVA). Coincubation of IGF-I (10 to 150 ng/ml) and
1a,25(OH)2D3 (10
28 M) prevented the increased DNA synthesis
induced by IGF-I, whereas coincubation with low-dose
1a,25(OH)2D3 (10
212 M) had an additive effect at all concentra-
tions tested in the experiment (Fig. 4). No additive effect of
Table 1. Regulation of IGF type-1 receptor: Specificity
Effector added
Specific bound
[125I]-aIR3
molecules/cell
Solvent 89,900 6 7500
IGF-I (48 hr) 243,900 6 23,200a
IGF-I (last 30 min) 38,800 6 12,300a
IGF-I 1 AB-1 113,000 6 6570b
IgG (anti-mouse) 121,000 6 11,900
Subconfluent chondrocytes, synchronized by preculture in serumfree
medium for 24 hr [and by implication in the absence of 1a,25(OH)2D3]
were cultured in F-12/DMEM 1/1 medium, 1.2 mmol nominal calcium
concentration with 0.2% BSA. IGF-I (60 ng/ml), AB-1 (1.25 mg/ml) or
both were added for the entire 48-hr culture period. Specific binding
[125I]-aIR3 was determined as described in the Methods section. As a
negative control, an unspecific anti-mouse IgG (1.25 mg/ml) was used.
AB-1 did not affect basal [125I]-aIR3 binding (data not given). The data
given in the Table are from one representative experiment out of three.
a P , 0.05 vs. solvent control; b P , 0.05 vs. IGF-I; statistics by ANOVA
(N 5 4).
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IGF-II and 1a,25(OH)2D3 on DNA-synthesis was found despite
the fact that stimulation of [3H]-thymidine incorporation by
IGF-II alone (10 to 60 ng/ml, data not given) was similar to IGF-I
action (Table 2).
The effect of 1a,25(OH)2D3 was stereospecific, since the ste-
reoisomer 1b,25(OH)2D3 was inactive (Table 2). Addition of the
polyclonal IGF-I antibody AB-1 attenuated the effect of coincu-
bation of IGF-I and 1a,25(OH)2D3. The AB-1 was specific for
IGF-I since the stimulatory effect of the third party growth factor,
that is, bFGF, was not significantly affected (Table 2). Increased
rate of [3H]-thymidine incorporation was associated with in-
creased alkaline phosphatase (AP) activity. Preincubation with
10212 M 1a,25(OH)2D3 for 48 hours increased AP activity from
18.0 6 2.1 nmol/well (BSA) to 41.3 6 2.5 nmol/well (P , 0.05),
and with IGF-I (60 ng/ml) to 38.5 6 5.9 nmol/well. Concomitant
incubation with 1a,25(OH)2D3 (10
212 M) and IGF-I (60 ng/ml)
caused a further significant increase in AP activity [48 6 3.5
nmol/well, P , 0.05 vs. IGF-I or 1a,25(OH)2D3 alone; statistics by
ANOVA].
Action of 1a,25(OH)2D3 and IGF-I on colony formation in
agarose-stabilized suspension cultures
Colony formation was significantly stimulated by 10% FCS
compared to control (0.2% BSA 1 0.1% FCS) treated cultures
(Fig. 5). Both 1a,25(OH)2D3 (10
212 M) and IGF-I (60 ng/ml)
added to BSA 1 0.1% FCS increased the colony formation
slightly above the 10% FCS positive control. Coincubation with
both 1a,25(OH)2D3 (10
212 M) and IGF-I (60 ng/ml) caused a
highly significant increase in colony number after 21 days of
culture (P , 0.01; Fig. 5).
Stimulation of VDR expression by 1a,25(OH)2D3 and IGF-I
Preincubation of subconfluent monolayer cultures for 24 hours
with various concentrations of IGF-I (20 ng/ml and 60 ng/ml)
caused a dose-dependent increase of maximal specific binding of
[3H]-1a,25(OH)2D3 (control 2424 bound molecules/cell; IGF-I 20
ng/ml 3574; IGF-I 60 ng/ml 12,000, without change of apparent
receptor affinity; Table 3 and Figs. 1B and 6). In contrast, IGF-II
(60 ng/ml) caused only a minimal change in maximal specific
binding (135% of control; Fig. 6). The IGF-I induced increase in
[3H]-1a,25(OH)2D3-binding was blocked by concomitant actino-
mycin D (2.5 mg/ml; Table 3). Addition of IGF-I (60 ng/ml) to the
medium did not increase VDR mRNA (Fig. 1B). In contrast,
incubation of subconfluent chondrocyte cultures with
1a,25(OH)2D3 10
212 M, but not 1028 M for 12 hours increased
VDR mRNA 1.5-fold (Fig. 1B). The effect of IGF-I and
1a,25(OH)2D3 on VDR expression was independently examined
using immune staining with monoclonal antibody (mAb) 9A7g.
Light and scarrous staining was seen in 0.2% BSA controls, while
preincubation with IGF-I (60 ng/ml), 1a,25(OH)2D3 (10
212 M)
and IGF-I 1 1a,25(OH)2D3 resulted in consistent intense recep-
tor staining (not shown).
DISCUSSION
The results of the present study provide evidence that the
somatotropic system, that is, IGF-I and the calcium regulatory
system, that is, 1a,25(OH)2D3, interact with respect to prolifera-
tion and receptor regulation in growth cartilage chondrocytes.
They mutually amplify their effects in this system. Cooperation
between these two hormone systems has thus far been described
in osteoblasts [29, 30] but has not been recognized in growth
cartilage. This finding has potential clinical implications.
The main finding of the study is the documentation that
1a,25(OH)2D3 increased the effects of IGF-I on (i) IGFIR
expression, (ii) DNA synthesis, (iii) cell proliferation/colony for-
mation, and (iv) activity of AP. These additive responses were
dose-dependent for IGF-I and noted only at low concentrations of
1a,25(OH)2D3 (10
212 M) close to the physiological range. We
emphasize that our BSA system did not contain endogenous
vitamin D metabolites or binding protein [10, 31]. The presence of
Fig. 1. Insulin-like growth factor type-1
receptor (IGFIR) mRNA and vitamin D
receptor (VDR) mRNA analyzed by reverse
transcriptase-polymerase chain reaction (RT-
PCR). Influence of IGF-I and 1a,25(OH)2D3.
Subconfluent chondrocyte monolayer cultures
were synchronized in serum-free medium for 24
hours. Medium was then changed to
F12/DMEM 1/1 containing 0.2% BSA. Cells
were incubated with ethanol (solvent, 0.05%
final concentration), IGF-I (60 ng/ml), or
1a,25(OH)2D3 (10
212 M and 1028 M) for the
indicated periods. Thereafter, total RNA was
prepared and mRNA levels encoding the
IGFIR or VDR were quantitated by RT-PCR
as described in the Methods section. (A) The
increase of the IGFIR mRNA by
1a,25(OH)2D3 10
212 M, but not 1028 M after 24
hours. (B) VDR mRNA was up-regulated by
1a,25(OH)2D3 10
212 M, but not 1028 M after 12
hours. The RT-PCR amplification products are
detected by electrophoresis in a 2% agarose gel
and were visualized by ethidium bromide
staining and ultraviolet transillumination (lower
panel). Results are given as mean 6 SEM of the
IGFIR/b-actin mRNA ratio or VDR/b-actin ratio
respectively of three to four separate experiments.
Statistics were by ANOVA. *P , 0.05.
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Fig. 2. Immunocytology of insulin-like growth factor type-1 receptor (IGFIR) in cultured growth plate chondrocytes. Primary cultures of growth plate
chondrocytes were kept in serum-free medium for 24 hours. Medium was changed to F-12/DMEM 1/1 supplemented with 0.2% BSA. (A) Solvent, (B)
IGF-I 60 ng/ml, (C) 1a,25(OH)2D3 10
212 M, or (D) both hormones together were added for 24 hours. Cell were fixed with paraformaldehyde (3.7%)
and incubated with the mAb aIR3 at a final dilution of 1:100. The bound aIR3 was visualized by the streptavidin-biotin technique. An increased
percentage of stained cells in the hormone treated groups is shown. Negative control were performed using a polyclonal IgG of the same subclass (not
shown). Magnification 3400.
serum as described by other authors [32, 33] was not necessary in
short term experiments (48 hr) to demonstrate a stimulation of
DNA synthesis by IGF-I, confirming the results of Bo¨hme at al
[34]. In contrast to Bo¨hme et al, we saw a stimulatory effect of
IGF-I in less than three days. The discrepancies are difficult to
explain, but may be due to persistent effects of serum (-factors),
present in the incubation medium prior to the FCS deprivation
(“starvation”) step. Such prolonged actions have been demon-
strated for 1a,25(OH)2D3 [35, 36] and glucocorticoids [37].
The mechanisms by which 1a,25(OH)2D3 amplified the prolif-
erative effect of IGF-I deserves comment. IGFIR expression was
not increased on the mRNA level, but markedly on the protein
level (binding studies) by 10212 M 1a,25(OH)2D3. On immunocy-
tochemical studies, qualitative observations suggested increased
single cell staining for aIR3, but the major effect was the presence
of more aIR3-positive cells upon treatment with 1a,25(OH)2D3.
In these experiments, the total number of cells did not increase
within 24 to 48 hours, suggesting recruitment of IGFIR positive
Fig. 3. Modulation of [125I]-aIR3-binding by
1a,25(OH)2D3, IGF-I or their combination.
Symbols are: () 1a,25(OH)2D3 at 10
212 M 1
IGF-I 60 ng/ml; (E) 1a,25(OH)2D3 at 10
212 M;
() IGF-I 60 ng/ml; (F) 1a,25(OH)2D3 at 10
28;
(X) control. Subconfluent chondrocytes,
synchronized by preculture in serum-free
medium for 24 hours [and by implication in the
absence of 1a,25(OH)2D3] were cultured in F-
12/DMEM 1/1 medium, 1.2 mmol nominal
calcium concentration with 0.2% BSA.
1a,25(OH)2D3 at 10
212 M or 1028 M were
added for the entire 48-hour culture period.
Specific binding [125I]- aIR3 was determined as
described in the Methods section.
1a,25(OH)2D3 10
212 M, but not 1a,25(OH)2D3
1028 M increased specific binding of [125I]-aIR3
without change in affinity. Nmax solvent control
89,800 molecules/cell; 1a,25(OH)2D3 10
212 M,
257,242; 1a,25(OH)2D3 10
28 M, 89,880; IGF-I,
243,960; 1a,25(OH)2D3 1 IGF-I, 459,672; Kd
solvent control, 0.95 3 1029 M; 1a,25(OH)2D3
10212 M, 1.8; 1a,25(OH)2D3 10
28 M, 1.8; IGF-I,
1.77; 1a,25(OH)2D3 1 IGF-I, 2.1.
Fig. 4. Modulation of [3H]-thymidine incorporation by IGF-I (–), 1
224,25(OH)2D3 (solid line) or their combination (z-z). Subconfluent chon-
drocyte cultures were starved by incubation in serum-free medium for 24
hours. After changing the medium to F12/DMEM 1/1 with 0.2% BSA
IGF-I (0 to 150 ng/ml) with or without 1a,25(OH)2D3 (10
212 to 1028 M)
was added for the entire 48-hour incubation period as indicated. [3H]-
thymidine (2 mCi/well) was added for the last four hours. The graph shows
additive effects of 1a,25(OH)2D3 (10
212 M) and IGF-I (60 ng/ml). The
high concentration (1028 M) of 1a,25(OH)2D3 also inhibited the effect of
IGF-I alone. Statistics were by ANOVA, N 5 8 per group. *P , 0.05
versus IGF-I; #P , 0.05 versus solvent control (IGF-I 0 ng/ml).
Table 2. Action of IGF-I, 1a,25(OH)2D3 on DNA synthesis: Specificity
Effector added
[3H]-thymidine incorporation
% of solvent control
Solvent 100 6 6
IGF-I 181 6 4a
1a,25(OH)2D3 175 6 5
a
1b,25(OH)2D3 105 6 7
IGF-I 1 1a,25(OH)2D3 220 6 10
a,b
IGF-I 1 1b,25(OH)2D3 153 6 12
a,c
AB-1 106 6 3
IGF-I 1 AB-1 110 6 3
IGF-I 1 1b,25(OH)2D3 1 AB-1 109 6 7
d
IGF-II 183 6 9a
IGF-II 1 1a,25(OH)2D3 180 6 5
a,c
bFGF 172 6 5a
bFGF 1 AB-1 179 6 3a
Cell cycles of subconfluent chondrocyte cultures were synchronized by
incubation in serum-free medium for 24 hr. After changing the medium to
F12/DMEM 1/1 with 0.2% BSA IGF-I (60 ng/ml), IGF-II (60 ng/ml),
1a,25(OH)2D3 (10
212 M), 1b,25(OH)2D3 (10
212 M) with or without
polyclonal IGF-I antibody AB-1 (1.25 mg/ml) or bFGF (10 ng/ml) were
added as indicated. [3H]-thymidine (2 mCi/well) was added for the last 4
hours of the 48-hr incubation period. Statistics by ANOVA, N 5 8 per
group.
a P , 0.01 vs. solvent control
b P , 0.05 vs. IGF-I or Ia,25(OH)2D3
c P , 0.05 vs. IGF-I 1 Ia,25(OH)2D3
d P , 0.05 vs. IGF-I 1 1b,25(OH)2D3
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cells as an important component of the action of 1a,25(OH)2D3.
Whether recruitment of IGFIR-positive cells is a reflection of cell
differentiation cannot be decided from the above data, because
the primary cultures used are inherently heterogeneous. Alterna-
tively, the additive effects of IGF-I and 1a,25(OH)2D3 could be
explained by distinct responsive subpopulations, which might be
recruited by either hormone alone. Stimulation of AP activity by
both 1a,25(OH)2D3 and IGF-I would argue for chondrocyte
maturation. The lack of modulation of IGFIR on the mRNA and
on protein level as well as the absence of proliferative effects of
IGF-I during coincubation with high-dose (1028 M) 1a,25(OH)2D3
is surprising. The mechanisms involved remain unexplained, but
this finding is in line with our previous observation of a biphasic
effect of 1a,25(OH)2D3 on proliferation [10, 15, 31]. The in vitro
antiproliferative effect of high concentrations of 1a,25(OH)2D3
(1028 M) has previously been documented by our laboratory [10,
38] and others [39–44].
The stimulatory effect of 1a,25(OH)2D3 on DNA synthesis was
specific, because this was not seen with the stereoisomer
1b,25(OH)2D3. Figure 4 shows that the effects of IGF-I and
1a,25(OH)2D3 were additive. This indicates that the two agonists
operate, at least in part, through separate effectors or pathways.
Some effects of 1a,25(OH)2D3 are mediated by nongenomic
mechanisms [45–48]. In single cell studies we found a slow, long
lasting increase in free ionized intracellular calcium within two
minutes after exposure to 1a,25(OH)2D3 [49]. Furthermore, we
demonstrated in previous studies that stimulation of growth by
1a,25(OH)2D3 was dependent on transmembrane calcium flux
through L-type voltage gated channels [31] arguing for rapid
actions of 1a,25(OH)2D3. However, the effect of 1a,25(OH)2D3
on increased [125I]-aIR3 binding was obliterated by actinomycin
D, suggesting that nuclear mechanisms are involved despite the
fact that only minor changes in IGFIR mRNA were detected.
Within the precision of our methods, the increase in IGFIR
mRNA tended to be smaller than the increase in [125I]-aIR3
binding. We cannot decide whether this discrepancy is due to
stabilization of IGFIR mRNA by 1a,25(OH)2D3 or to the long
half life of IGFIR mRNA (Rodrı´guez, unpublished observation).
The signal transduction sequences involved in the interaction
between somatotropic and calciotropic hormones on growth
cartilage chondrocytes have not yet been elucidated. To the best
of our knowledge, no calcium- or 1a,25(OH)2D3-sensitive re-
sponse sequences have been documented in the IGFIR gene.
Furthermore, IGF-I failed to affect binding of the VDR to its
cognate response element in osteosarcoma cells [50].
We visualized and quantitated the IGF-I receptor in rat (and
rabbit) cells by binding with a mAb directed against the human
IGFIR, that is, mAb aIR3. Binding was specific since hepatocytes
of two-month-old rats that practically do not express IGFIR failed
to stain; furthermore, staining was obliterated by an excess of cold
IGF-I, while excess of IGF-II did not affect immune staining.
When evaluating aIR3 binding by chondrocytes, we were con-
cerned about the confounding effect of potential IGF-I synthesis
by chondrocytes. Under the basal conditions of the experiment,
little IGF-I (0.16 ng/ml) was found in the supernatant. At this
concentration, no inhibition of aIR3 binding was noted in control
experiments (data not given).
The additive effect of IGF-I and 1a,25(OH)2D3 on chondrocyte
proliferation and AP activity resembles previous observations
Fig. 5. Effect of 1a,25(OH)2D3, IGF-I, and their combination on colony
formation. Symbols are: () 1a,25(OH)2D3 10
212 M 1 IGF-I 60 mg/ml;
() IGF-I 60 ng/ml; (E) 1a,25(OH)2D3 10
212 M; (F) 10% FCS; (X)
control. Chondrocytes were cultured in agarose stabilized suspension as
described in the Methods section. F-12/DMEM 1/1 medium, 1.2 mmol
nominal calcium concentration supplemented with 0.2% BSA and 0.1%
FCS was changed every other day. 1a,25(OH)2D3 10
212 M dissolved in
ethanol or ethanol alone as solvent control or IGF-I 60 ng/ml dissolved in
PBS or PBS were added. A further group was coincubated with
1a,25(OH)2D3 10
212 M and IGF-I 60 ng/ml. As a positive control, 10%
FCS addition to the medium was used. Cultures were terminated after 21
days by fixation in buffered formaldehyde (4%) and colonies stained with
alcian blue. The colonies were counted in 100 squares of a 2 mm grid using
an inverted light microscope. Cloning efficiency was calculated from
colonies formed/1000 seeded cells. Data are mean 6 SD of six dishes.
Statistics were by ANOVA. Data are from one representative experiment.
*P , 0.05 IGF-I versus IGF-I 1 1a,25(OH)2D3; **P , 0.05
1a,25(OH)2D3 versus IGF-I 1 1a,25(OH)2D3;
#P , 0.05 versus solvent
control.
Table 3. Effect of actinomycin D on IGF-I induced up-regulation of
vitamin D receptor (VDR)
Effector added
Nmax
molecules/cell
Kd
10210 M
Solvent 2327 4.3
IGF-I 12287 3.4
Actinomycin D 2918 6.2
IGF-I 1 actinomycin D 4438 6.3
Subconfluent chondrocytes, synchronized by preculture in serum free
medium for 24 hr [and by implication in the absence of 1a,25(OH)2D3]
were cultured in F-12/DMEM 1/1 medium, 1.2 mmol nominal calcium
concentration with 0.2% BSA and IGF-I (60 ng/ml final concentration)
added for the entire 24-hr culture period. Incubation with actinomycin D
(2.5 mg/ml) was performed for the first 16 hours, followed by 3 washes.
Postincubation was performed in the presence or absence of IGF-I (60
ng/ml). Specific binding of [3H]-1a,25(OH)2D3 was determined in KTED
whole cell extracts as described in the Methods section.
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indicating that the action of IGF-I is also amplified by other
growth factors in vivo [51]. In osteoblast cell lines synergism of
IGF-I and 1a,25(OH)2D3 on alkaline phosphatase activity and
collagen synthesis was reported [29]. Similar observations on
alkaline phosphatase activity and Gla protein secretion were
made in cultivated human bone cells [30]. In contrast, supplemen-
tation of 1a,25(OH)2D3 normalized growth in vitamin D deficient
rats without any change in serum IGF-I concentrations, although
circulating IGF-I levels may not necessarily reflect local IGF-I
concentrations in the growth plate (paracrine secretion) [52].
Furthermore, effects of IGF-binding proteins modulating IGF-I
action [53–55] were not excluded.
Chondrocytes in primary culture express VDR as shown previ-
ously [10, 18]. Incubation of the cultures with IGF-I increased the
binding of radiolabeled 1a,25(OH)2D3. This effect was stereo-
specific. It was not the result of increased chondrocyte prolifera-
tion induced by IGF-I, because IGF-II stimulated DNA synthesis
to a similar extent as IGF-I, but did not affect VDR expression.
These observations are in line with studies reporting up-regula-
tion of VDR by IGF-I in 3T3 fibroblasts and in human breast
cancer cells [56]. The intriguing selectivity for IGF-I versus IGF-II
in VDR up-regulation and in additive action with 1a,25(OH)2D3
on proliferation cannot be explained by our results. However, the
affinity of IGF-I for the IGFIR normally is higher than that of
IGF-II as demonstrated in articular chondrocytes [57] and bone
cells [reviewed in 58]. In our study we were not able to mimic all
of the effects of IGF-I by high concentrations of IGF-II as
demonstrated in osteosarcoma cells [59]. This suggests a selective
action of IGF-I via IGFIR. We could demonstrate IGFIR expres-
sion not only in cultured cells, but also ex vivo in rat tibial growth
plates (results not shown). These findings are in contrast to results
obtained by Schalch et al, who described action of IGF-I via the
type 2 IGF/mannose-6-phosphate receptor on costal chondrocytes
[60]. These differences might be due to cell source, cell culture
condition and maturation state of cells used.
Our study confirms that the increase in VDR precedes the rise
in DNA synthesis [31]. As shown previously [19], short-term
incubation of chondrocytes with 1a,25(OH)2D3 at low concentra-
tions causes homologous up-regulation of specific binding of
1a,25(OH)2D3. Significant regulation of VDR protein stability
was described in osteoblasts [61]. Although the effect of IGF-I on
VDR protein expression measured by radioligand binding was
dependent on transcription, as shown by inhibition by actinomycin
D, we could not demonstrate an increase of VDR mRNA upon
incubation with IGF-I. This suggests that VDR protein up-
regulation occurred primarily independent of VDR mRNA accu-
mulation. Therefore, an expression of a costimulatory subunit
such as retinol X receptor [reviewed in 62] and/or translational
modification of the VDR transcript might participate in the
significant up-regulation of VDR protein observed.
We considered several possibilities to explain stimulation of
1a,25(OH)2D3 binding by IGF-I. Cell morphology assessed by
phase contrast microscopy showed no major alteration in the cell
geometry. We further indirectly assessed whether IGF-I might
have altered the amount of plasma membrane available for aIR3
binding: no change in cell protein content (as a rough index of cell
hypertrophy) and no morphological evidence of cell hypotrophy
were found. Furthermore, analysis of the supernatant for de-
tached cells was consistently negative. We measured DNA syn-
thesis, an index of chondrocyte proliferation after stimulation with
IGF-I and 1a,25(OH)2D3, respectively. These measurements
were carried out in cells cultured in 0.2% BSA to avoid the
confounding influence of IGF and vitamin D metabolites, respec-
tively, which are present in FCS. Under these conditions, how-
ever, cells did not replicate in a time frame of two days and started
to deteriorate after 72 hours. While IGF-I was effective in
stimulating cell proliferation, it additionally increased activity of
alkaline phosphatase as a marker of chondrocyte differentiation,
in contrast to what had previously been observed in chicken
chondrocytes [34]. Further evidence of induction of cell differen-
tiation by IGF-I was provided by the observation of stimulated
colony formation in long-term cultures incubated with IGF-I.
In the clinical setting of growth retardation due to chronic renal
failure in children, disturbances of the vitamin D system and the
somatotropic axis are simultaneously present [11]. If the additive
effects of IGF-I and 1a,25(OH)2D3 can be confirmed in vivo,
restoration of both 1a,25(OH)2D3 and GH/IGF status may be
required to fully restore abnormal growth in these children. Our
Fig. 6. Modulation of [3H]-1a,25(OH)2D3-
binding by IGF-I and IGF-II. Symbols are: ()
IGF-I; () IGF-II; (F) control. Subconfluent
chondrocytes, synchronized by preculture in
serum-free medium for 24 hours (and by
implication in the absence of 1a,25(OH)2D3)
were cultured in F-12/DMEM 1/1 medium, 1.2
mmol nominal calcium concentration with 0.2%
BSA and 0.1% FCS. IGF-I (60 ng/ml final
concentration) or IGF-II (60 ng/ml) were added
for the entire 48-hour culture period. Specific
binding of [3H]-1a,25(OH)2D3 was determined
in KTED whole cell extracts as described in the
Methods section. IGF-I, but not IGF-II
increased maximal specific binding of [3H]-
1a,25(OH)2D3 without changes in KD. One
representative experiment is shown. Nmax
solvent control, 2424 bound molecules/cell;
IGF-I, 12,000; IGF-II, 3320. Kd solvent control,
5.7 3 10210 M; IGF-I, 5.7; IGF-II, 5.8.
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in vitro experiments also suggest mutual inhibition of the interac-
tion when high concentrations of 1a,25(OH)2D3 are achieved.
There is no documentation for this possibility, but it should be
considered in the light of our recent animal experiments, in which
daily low dose 1a,25(OH)2D3 increased the GH effect on uremic
growth retardation, while high dose 1a,25(OH)2D3 (pulse ther-
apy) did not [63].
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APPENDIX
Abbreviations used in this article are: AB-1, polyclonal IGF-I antibody;
AP, alkaline phosphatase activity; FCS, fetal calf serum; GH, growth
hormone; IGF, insulin-like growth factor; IGFIR, IGF-type 1 receptors;
LGT, low gel temperature; mAb, monoclonal antibody; RT-PCR, reverse
transcriptase-polymerase chain reaction; SL, standard low gel tempera-
ture; VDR, vitamin D receptor.
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